ERYtech Pharma Receives Authorization To Start Its Phase II Clinical Study In Pancreatic Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news